Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.
Saved in:
| Title: | Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics. |
|---|---|
| Authors: | Block TM; Hepatitis B Foundation and Baruch S. Blumberg Institute, Doylestown, Pennsylvania, USA., Locarnini S; Victorian Infectious Diseases Reference Laboratory, Doherty Institute, Melbourne, Australia., McMahon BJ; Alaska Native Health Center, Anchorage, USA., Rehermann B; Immunology Section, Liver Diseases Branch, National Institutes of Health, Bethesda, Maryland, USA., Peters MG; Department of Medicine, University of California, San Francisco, USA. |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2017 May 01; Vol. 64 (9), pp. 1283-1288. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/cix129 |
